Lambert-Eaton Myasthenic Syndrome (LES)

Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase lll Clinical Trial for Firdapse(TM) CORAL GABLES, Fla., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase III clinical trial in the United States and Europe evaluating Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the Company continue the trial as planned based on the committee's review of safety and clinical data from the trial. The DMC is a group of experts responsible for the independent review of accumulated, unblinded clinical safety and effica

Catalyst Pharmaceutical Announces Social Media Presence - WSJ.com Catalyst Pharmaceutical Announces Social Media Presence!!! Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced that it has joined the social media conversation with a company blog and Twitter handle, which can be found at CatalystPharmaBlog.com and @CatalystPharma respectively. "We are embracing social media to engage with and better understand the patient communities we intend to serve," said Patrick J. McEnany, Chairman and CEO of Catalyst. "We are developing drugs for patients with rare, orphan diseases, and that means we need to go beyond traditional methods of communications to reach and learn from these patients, their families and their care providers." Catalyst will use these social media channels to foster conversations be

Catalyst Pharma updates on Firdapse development activities

The Myasthenia Gravis Association will be supporting Rare Disease Day 2014 on Friday 28 February as a way of raising awareness of Myasthenia Gravis.  The association’s next support group meeting will take place on Thursday 6 March at Demesne Media Arts Centre, Bowness Road, Middleton, M24 4NU at 7.30pm. The Myasthenia Gravis Association exists to promote the welfare of suffers from Myasthenia Gravis, Lambert- Eaton Myasthenic Syndrome (LEMS) and CMS Congenital Myasthenic Syndrome throughout the United Kingdom and the Republic of Ireland.  Myasthenia Gravis is a neuro-muscular condition that affects approximately 1 in 10,000 people in the UK. Myasthenia Gravis is a condition characterised by fluctuating muscle weakness, which in rare cases may be fatal, particularly if left untreated.  Regional Organiser Sarah Sanders said: “There are over 600 people with Myasthenia Gravis in the North West Region and so many more that we are not currently aware of.”  Myasthenia Gravis, like most rare

Catalyst Pharmaceutical Partners Observes Rare Disease Day Today - WSJ.com

Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference - MarketWatch

Narrower-than-Expected Loss at Catalyst Pharma - March 20, 2014 - Zacks.com